Carl Schmid discusses the implications of the USPSTF Grade A rating of HIV PrEP to patients, providers, and payers.
This multi-stakeholder roundtable panel discussion will focus on how to address barriers and disparities as obstacles to the use of PrEP, with a focus on increased understanding and education around US Preventive Services Task Force (USPSTF) PrEP guidelines and Affordable Care Act Part 47 for payers and providers.
Examines how insurance benefit design, including high deductibles and co-insurance, impact prescription drug access, along with the importance of copay assistance and how states are ensuring that it count towards beneficiary cost-sharing obligations.
Discusses how HIV prevention and treatment policy influence broader health policy issues in commemoration of World AIDS Day 2021.
Details policies and programs needed to ensure and promote PrEP access to #endHIV: reviewing insurance plans to see if they follow the ACA requirement to cover PrEP w/o patient cost-sharing, the need for greater funding of @CDC_HIVAIDS & community health centers, & potential USPSTF evaluation of long-acting PrEP products